Alloantigen-stimulated induction and release of CD30 in patients with end-stage renal failure

Human Immunology

Volumn 73, Issue 11, 2012, Pages 1102-1108

  Velásquez, Sonia Y ^a   Süsal, Caner ^b   Opelz, Gerhard ^b   García, Luis F ^a   Alvarez, Cristiam M ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CD30 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN CELL; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIGENS, CD30; CASE-CONTROL STUDIES; FEMALE; HUMANS; ISOANTIGENS; KIDNEY FAILURE, CHRONIC; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; T-LYMPHOCYTES, REGULATORY;

EID: 84867850045     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.08.015     Document Type: Article

References (46)

1. Smith C.A., Gruss H.J., Davis T., Anderson D., Farrah T., Baker, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993, 73:1349-1360.
2. Durkop H., Latza U., Hummel M., Eitelbach F., Seed B., Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992, 68:421-427.
3. Horie R., Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998, 10:457-470.
4. Del Prete G., De Carli M., Almerigogna F., Daniel C.K., D'Elios M.M., Zancuoghi G., et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 1995, 9:81-86.
5. Agrawal B., Reddish M., Longenecker B.M. CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors. J Immunol 1996, 8:3229-3234.
6. Manetti R., Annunziato F., Biagiotti R., Giudizi M.G., Piccinni M.P., Giannarini L., et al. CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection. J Exp Med 1994, 180:2407-2411.
7. Hamann D., Hilkens C.M., Grogan J.L., Lens S.M., Kapsenberg M.L., Yazdanbakhsh M., et al. CD30 expression does not discriminate between human Th1- and Th2-type T cells. J Immunol 1996, 156:1387-1391.
8. Ellis T.M., Simms P.E., Slivnick D.J., Jack J.M., Fisher R. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol 1993, 151:2380-2389.
9. Hansen H.P., Kisseleva T., Kobarg J., Horn-Lohrens O., Havsteen B., Lemke H. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer 1995, 63:750-756.
10. Hansen H.P., Dietrich S., Kisseleva T., Mokros T., Mentlein R., Lange H.H., et al. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-α-converting enzyme. J Immunol 2000, 165:6703-6709.
11. Gruss H.J., Pinto A., Duyster J., Poppema S., Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today 1997, 18:156-163.
12. Zanotti R., Trolese A., Ambrosetti A., Nadali G., Visco C., Ricetti M.M., et al. Serum levels of soluble CD30 improve international prognostic score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol 2002, 13:1908-1914.
13. Nishioka C., Takemoto S., Kataoka S., Yamanaka S., Moriki T., Shoda M., et al. Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma. Cancer Sci 2005, 96:810-815.
14. Monsalve-De Castillo F., Romero T.A., Estévez J., Costa L.L., Atencio R., Porto L., et al. Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases. Clin Diagn Lab Immunol 2002, 9:1372-1375.
15. Pizzolo G., Vinante F., Nadali G., Krampera M., Morosato L., Chilosi M., et al. High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol 1997, 108:251-253.
16. Okumura M., Hidaka Y., Kuroda S., Takeoka K., Tada H., Amino N. Increased serum concentration of soluble CD30 in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 1997, 82:1757-1760.
17. Gerli R., Pitzalis C., Bistoni O., Falini B., Costantini V., Russano A., et al. CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol 2000, 164:4399-4407.
18. Süsal C., Pelzl S., Dohler B., Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002, 13:1650-1656.
19. Pelzl S., Opelz G., Wiesel M., Schnülle P., Pschönemann C., Döhler B., et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002, 73:3-6.
20. Rodriguez L.M., Paris S.C., Arbeláez M., Cotes J.M., Süsal C., Torres Y., et al. Kidney graft recipients with pretransplantation HLA class I antibodies and high soluble CD30 are at high risk for graft loss. Hum Immunol 2007, 68:652-660.
21. Süsal C., Döhler B., Sadeghi M., Salmela K.T., Weimer R., Zeier M., et al. Posttrasplant sCD30 as a predictor of kidney graft outcome. Transplantation 2011, 91:1364-1369.
22. Weimer R., Süsal C., Yildiz S., Staak A., Pelzl S., Renner F., et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 2006, 6:1865-1874.
23. Wang D., Wu G.J., Wu W.Z., Yang S.L., Chen J.H., Wang H., et al. Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection. Transpl Immunol 2007, 17:278-282.
24. Hargreaves P.G., Al-Shamkhani A. Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur J Immunol 2002, 32:163-173.
25. Tarkowski M. Expression and a role of CD30 in regulation of T-cell activity. Curr Opin Hematol 2003, 10:267-271.
26. Zeiser R., Nguyen V.H., Hou J.Z., Beilhack A., Zambricki E., Buess M., et al. Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood 2007, 109:2225-2233.
27. Dai Z., Li Q., Wang Y., Gao G., Diggs L.S., Tellides G., et al. CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J Clin Invest 2004, 113:310-317.
28. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245-1253.
29. Yagi H., Nomura T., Nakamura K., Yamazaki S., Kitawaki T., Hori S., et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004, 16:1643-1656.
30. Saxena A.K., Panhotra B.R. Hemodialysis catheter-related bloodstream infections: current treatment options and strategies for prevention. Swiss Med Wkly 2005, 135:127-138.
31. Hung A.M., Ikizler T.A. Hemodialysis central venous catheters as a source of inflammation and its implications. Semin Dial 2008, 21:401-404.
32. Meier P., von Fliedner V., Markert M., van Melle G., Deppisch R., Wauters J.P. One-year immunological evaluation of chronic hemodialysis in end-stage renal disease patients. Blood Purif 2000, 18:128-137.
33. Kaul H., Girndt M., Sester U., Sester M., Köhler H. Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. Am J Kidney Dis 2000, 35:611-616.
34. Gerli R., Muscat C., Bistoni O., Falini B., Tomassini C., Agea E., et al. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol 1995, 102:547-550.
35. Delfanti F., Veglia F., Poli G., Lazzarin A., Biswas P. Ex vivo modulation of RANTES and sCD30 by proinflammatory stimuli in HIV-seropositive and -negative individuals. Clin Immunol 2000, 97:102-108.
36. Alvarez C.M., Opelz G., Garcia L.F., Susal C. Expression of regulatory T-cell-related molecule genes and clinical outcome in kidney transplant recipients. Transplantation 2009, 87:857-863.
37. Hendrikx T.K., van Gurp E.A., Mol W.M., Schoordijk W., Sewgobind V.D., Ijzermans J.N., et al. End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells. Nephrol Dial Transplant 2009, 24:1969-1978.
38. Saini D., Ramachandran S., Nataraju A., Benshoff N., Liu W., Desai N., et al. Activated effector and memory T cells contribute to circulating sCD30: potential marker for islet allograft rejection. Am J Transplant 2008, 8:1798-1808.
39. Hauser A.B., Stinghen A.E., Kato S., Bucharles S., Aita C., Yuzawa Y., et al. Characteristics and causes of immune disfunction related to uremia and dialysis. Perit Dial Int 2008, 28:S183-S187.
40. Girndt M., Sester M., Sester U., Kaul H., Köhler H. Molecular aspects of T- and B-cell function in uremia. Kidney Int 2001, 78:S206-S211.
41. Lange T., Dimitrov S., Born J. Effects of sleep and circadian rhythm on the human immune system. Ann N Y Acad Sci 2010, 1193:48-59.
42. Lee S., Kim J., Jang B., et al. Fluctuation of peripheral blood T, B, and NK cells during a menstrual cycle of normal healthy women. J Immunol 2010, 185:756-762.
43. Altermann W., Schlaf G., Rothhoff A., Seliger B. High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?. Nephrol Dial Transplant 2007, 22:2795-2799.
44. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
45. de Kleer I., Vercoulen Y., Klein M., Meerding J., Albani S., van der Zee R., et al. CD30 discriminates heat shock protein 60-induced FOXP3+ CD4+ T cells with a regulatory phenotype. J Immunol 2010, 185:2071-2079.
46. Hansen H.P., Recke A., Reineke U., Von Tresckow B., Borchmann P., Von Strandmann E.P., et al. Ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5. FASEB J 2004, 18:893-895.